Navigation Links
MannKind Corporation Response to Recent Market Events
Date:3/10/2008

f meal-time insulin observed in healthy individuals, but which is absent from patients with diabetes. MannKind believes that by mimicking the normal physiologic release of meal-time insulin, Technosphere(R) Insulin will be positioned as the only insulin therapy that effectively addresses post-prandial glucose excursions.

MannKind is only beginning to explore the opportunities associated with the ability to deliver a peptide hormone in ways that mimic normal hormone physiology. The data from MannKind's pivotal Phase 3 trials of Technosphere(R) Insulin will start to become available in the third quarter of 2008. In the meantime, in a Phase 1 trial of MKC253, another Technosphere(R)-based product, blood levels of GLP-1 were observed to peak within three minutes of administration, which may mimic the natural short pulse of GLP-1 that is produced in a healthy individual in response to glucose ingestion. Following administration of MKC253, study subjects experienced a dose-dependent increase in insulin levels and a decrease in glucose levels. Even at the highest doses of MKC253, subjects did not report any sweating, nausea or vomiting whereas those side effects are associated with the use of injectable GLP-1 products that do not mimic the natural, pulsatile feature of this hormone. These data will be presented in detail at the upcoming meeting of the American Diabetes Association.

MannKind believes that a significant need exists for products that offer efficacy and safety advantages in the delivery of peptide hormones. MannKind is committed to continuing the clinical development of Technosphere(R) Insulin and MKC253. A third peptide hormone for the treatment of obesity is in preclinical development. Currently, MannKind has sufficient financial resources to fund these programs and others through the end of 2009. It is MannKind's intention to bring these treatments to patients in collaboration with a leading pharmaceutical partner who shares a commitment to im
'/>"/>

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. MannKind to Present at the UBS Global Life Sciences Conference
2. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
3. MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
4. MannKind to Present at the Piper Jaffray Healthcare Conference
5. MannKind to Present at the Wachovia 2008 Healthcare Conference
6. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
7. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
8. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014  AuraSense Therapeutics, the pioneer in developing ... regulatory and immunotherapeutic agents, announced today that ... Therapeutics, executive leadership team as chief financial ... to joining AuraSense Therapeutics, Mr. Snyder was ... of Cellular Dynamics International Inc., where he ...
(Date:7/23/2014)... -- Having the right people at the table for significant ... and achieving clinical and operational goals. The 22 nd ... 20-22, 2014, in San Diego , ... experts discussing how partnerships have positively impacted their objectives. ... Executive Officer of Cape Regional Medical Center located in ...
(Date:7/23/2014)... , July 23, 2014 ... company of Trendlines Agtech , announced it ... Israel,s leading agricultural thermoplastics applications ... Valentis,s technology combines nanocrystalline cellulose (NCC), a ... with additional nanoparticles to produce highly improved polymeric ...
(Date:7/23/2014)... regulated information -- UCB today announced an ... with positive topline results from the latest Phase ... designed to evaluate the efficacy and safety of ... titration) compared to placebo, as adjunctive treatment in ... fully controlled despite treatment with one or two ...
Breaking Biology Technology:AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer 2MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7
... (NYSE:,DHR) announced that Executive Vice President and Chief ... the Robert W. Baird Industrial,Conference in Chicago, IL ... CST.,The audio will be simultaneously webcast on ... manufacturer of Professional,Instrumentation, Medical Technologies, Industrial Technologies and ...
... 4 Cambrex,Corporation (NYSE: CBM ) reports third quarter 2008 ... (Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO ), -- Sales increased 3.2% (-1.7% ... 2007. -- Adjusted EBITDA for the quarter was up $1.7 ... last year. -- Debt, net of cash was $92.0 million ...
... PRGO ; TASE) today announced that its Board of ... on December 16, 2008 to,shareholders of record on November ... represents a ten percent increase over $0.05 per share,paid ... a leading global healthcare supplier that develops,manufactures and distributes ...
Cached Biology Technology:Cambrex Reports Third Quarter 2008 Results 2Cambrex Reports Third Quarter 2008 Results 3Cambrex Reports Third Quarter 2008 Results 4Cambrex Reports Third Quarter 2008 Results 5Cambrex Reports Third Quarter 2008 Results 6Cambrex Reports Third Quarter 2008 Results 7Cambrex Reports Third Quarter 2008 Results 8Cambrex Reports Third Quarter 2008 Results 9Cambrex Reports Third Quarter 2008 Results 10Cambrex Reports Third Quarter 2008 Results 11Cambrex Reports Third Quarter 2008 Results 12Cambrex Reports Third Quarter 2008 Results 13Cambrex Reports Third Quarter 2008 Results 14
(Date:7/23/2014)... July 23, 2014 BioCatch, the ... announced today it has been named in Gartner,s Market ... Guide replaces Gartner,s well-known Magic Quadrant for Web Fraud ... as one of several vendors to deliver passive biometric ... become a standard feature of at least 30% of ...
(Date:7/23/2014)... increase in temperature around the world by 2050, according ... Panel on Climate Change (IPCC), may be advantageous to ... in the growth of forage plants such as ... grazing in tropical countries such as Brazil., The conclusion ... the Department of Biology at the Ribeiro Preto Faculty ...
(Date:7/23/2014)... bacterial group called SUP05 will play an increasingly important ... oceans as oxygen minimum zones expand, according to research ... National Academy of Sciences . , University of British ... fjord, Canada,s Saanich Inlet, to chart how microbial community ... study paints a very detailed picture of how SUP05 ...
Breaking Biology News(10 mins):BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 3An increase in temperature by 2050 may be advantageous to the growth of forage plants 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 3An increase in temperature by 2050 may be advantageous to the growth of forage plants 4Research charts the ecological impact of microbial respiration in the oxygen-starved ocean 2
... experts have been calling for an improved database that ... conservation strategies. Botanists at the University of Bonn have ... the publication, in the Journal of Biogeography, of a ... arranged in 867 zones, known as ecoregions. "This makes ...
... Clinic researchers have found that the cause of chronic sinus ... not in the nasal and sinus tissue targeted by standard ... of Journal of Allergy and Clinical Immunology and are ... been thought worldwide about the origin of chronic sinus infection: ...
... A team of researchers at the Universitat Autònoma de ... The sensors have the same size and thickness as ... DNA chains to several minutes or a few hours, ... to many different tasks, ranging from paternity tests and ...
Cached Biology News:Scientists map the world for nature conservation 2Chronic Sinus Infection Thought To Be Tissue Issue, Mayo Clinic Scientists Show It's Snot 2New miniaturised chip dramatically reduces time taken for DNA analysis 2New miniaturised chip dramatically reduces time taken for DNA analysis 3
... Expression is a powerful application ... Utilising a novel interface, Expression makes ... incredibly simple. Expression uses the very ... standards in the way sequences are ...
... Mouse Antibody to Human Cytokeratin TYPE II ... (Type II) keratins. Including epidermal cell keratin ... 58kD, 65kD and 67kD. Broad keratin reactivity ... and cornea. Immunogen: ...
... XpressPack™ Colorimetric Detection System is intended for ... DNA generated by an in-house validated in ... target of interest. • ... is a hybridization capture assay designed to ...
Mouse Anti-Human Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 (KIR2DL4 Monoclonal Antibody Family: New...
Biology Products: